Skip to main content
The driveway to the Kay Jewelers Pavilion on our Akron Campus will be closed for 2-4 weeks beginning Oct. 10. Click HERE for details.
Go to homepage

Perampanel in Children 1 month to 2 years

Safety and Efficacy of Perampanel in Children 1 month to 2 years

Description:

For complete study information, please view the study on clinicaltrials.gov

Interested in participating?
We are currently recruiting
Full IRB Study Title:
An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 24 Months (<2 years) of Age With Epilepsy
IRB Study ID:
1057929
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Michael Kohrman, MD

Director, Pediatric Neurology; Co-director, Tuberous Sclerosis Program; Pediatric Neurologist
Pediatric Epilepsy ProgramPediatric NeurologyTuberous Sclerosis ClinicNeuroDevelopmental Science CenterPediatric Sleep Center